LONDON (Alliance News) - US drugsmaker Pfizer Inc said Thursday that it has agreed a multi-year collaboration with GlaxoSmithKline PLC for the development of a next-generation of its current portable miniature prototype for oral sold dose pharmaceutical development and manufacturing.
Pfizer's current prototype is an autonomous, transportable pod, used for the production of tablets and capsules.
"Pfizer's success in building a first-of-a-kind, transportable, modular prototype for oral solid dose pharmaceutical development and manufacturing holds promise to help transform industry practices, and we invite other organisations to join us in this effort," said Pfizer's Senior Vice President of PharmaTherapeutics Research and Development Rod MackKenzie in a statement.
"We believe coupling Pfizer's industry-leading development and manufacturing capabilities with GSK's experience and expertise in continuous processing has the potential to lead to a superior technology, thereby allowing us to more quickly and efficiently bring therapies to patients," MacKenzie added.
Shares in GlaxoSmithKline were down 1.2% at 1,403.00 pence Thursday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.